| Literature DB >> 34250582 |
Koji Yamamoto1, Fumiki Yamashita1, Makiko Kawaguchi1, Aya Izumi1, Takumi Kiwaki1, Hiroaki Kataoka1, Takeshi Kaneuji2, Yoshihiro Yamashita2, Tsuyoshi Fukushima3.
Abstract
Prostasin is a glycosylphosphatidylinositol-anchored serine protease widely expressed in epithelial cells, with crucial epidermal barrier functions. Evidence has suggested prostasin may have served as a tumor suppressor in various cancers, but its role in oral squamous cell carcinoma (OSCC) remains unclear. Thus, herein, we conducted an immunohistochemical prostasin study in 119 resected OSCC cases. Prostasin expression was decreased in 63% (75/119) of cases. OSCC with decreased prostasin immunoreactivity (low prostasin cases) tended to show a higher histological grade (p = 0.0088) and a more infiltrative cancer cell morphology (p = 0.0024). We then explored the role of prostasin in the OSCC cell lines: SAS and HSC-4. SAS did not express detectable prostasin levels, whereas HSC-4 expressed low but distinct levels. Prostasin overexpression suppressed the proliferation and migration of both OSCC lines in vitro. Conversely, prostasin silencing significantly enhanced growth rates of HSC-4. Finally, we analyzed the impact of prostasin expression on the prognosis of patients with OSCC; decreased expression tended to correlate with shorter overall survival (p = 0.0291) after resection. This trend was supported by our analyses using a public database (Kaplan-Meier plotter) of head and neck squamous cell carcinomas. In conclusion, we showed decreased prostasin expression was associated with aggressive features and a poorer prognosis of OSCC.Entities:
Keywords: Epithelial–mesenchymal transition; Head and neck squamous cell carcinoma; Oral squamous cell carcinoma; Prognosis; Prostasin
Mesh:
Substances:
Year: 2021 PMID: 34250582 DOI: 10.1007/s13577-021-00575-3
Source DB: PubMed Journal: Hum Cell ISSN: 0914-7470 Impact factor: 4.174